British American Tobacco heads into its September 29 results with options traders more cautious than they have been in months, even as short sellers continue to retreat.
The sharpest pre-earnings signal is in options positioning. The put/call ratio jumped to 0.61 on Thursday — more than two standard deviations above its 20-day average of 0.51, the most defensive reading relative to recent norms all year. That shift is notable because it arrived sharply and recently: the PCR had been running in the 0.46–0.50 range for most of September before spiking this week. Meanwhile the stock has drifted lower — down about 1.5% over the past month and fractionally softer on the week at $55.63 — adding a modest price-action tailwind to the defensive skew.
Short interest, by contrast, tells a much calmer story. Bears have been covering, not building. Short interest fell nearly 8% in a single session on September 24 and is down almost half from a month ago, now at roughly 2.8 million shares. The lending market confirms there is no meaningful squeeze dynamic at work: borrow availability is essentially unlimited, with no realistic constraint on new short positions for anyone who wanted them. Borrowing cost is negligible at 0.44%, barely changed week-on-week. The ORTEX short score of 25.9 is stable and unremarkable — this is not a stock where short-side pressure is building into the print.
The fundamental debate is well-worn. Bulls lean on the defensive income case: a dividend score in the 86th percentile, a PE around 11x, and a quality factor propped up by balance sheet metrics that remain competitive within tobacco. Argus Research upgraded to Buy about a year ago with a $62 target, and both Jefferies and UBS have moved to bullish stances in the past year or two — though no major firm has acted within the past two weeks. Bears point to structural deterioration: forward earnings are under real pressure, with the 12-month forward EPS growth trajectory ranking in just the 16th percentile across the universe, and the analyst recommendation differential sits in the bottom decile at a score of 5. The costly transition toward reduced-risk products is consuming capital while combustible volumes continue their long decline. The last major earnings event in late July resulted in a 3.8% one-day drop followed by a further 7% over the following five sessions — a pattern worth holding in mind.
Tuesday's print is less a test of whether BAT can sustain its dividend and more a test of whether management's next-generation product revenue can show enough momentum to justify the stock's current valuation without a further de-rating of the forward earnings outlook.
See the live data behind this article on ORTEX.
Open BTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
